» Leczenie objawowe zakażeń dróg oddechowych

*Piotr Albrecht, Andrzej Radzikowski

Leczenie objawowe zakażeń dróg oddechowych

Symptomatic treatment of respiratory tract infections

Klinika Gastroenterologii i Żywienia Dzieci Warszawskiego Uniwersytetu Medycznego
Kierownik Kliniki: prof. nadzw. dr hab. med. Andrzej Radzikowski

Summary

Key words:

Piśmiennictwo

1. Simasek M, Blandino DA: Treatment of the common cold. Am Fam Physician 2007; 75: 515-520. 2. Radzikowski A, Albrecht P: Leczenie objawowe zakażeń dróg oddechowych - podstawy patofizjologiczne i strategia postępowania. Pediatr Pol 1998; 73: 1-8. 3. Zió-kowski J, Zió-kowska H: Ból i zastosowanie paracetamolu u dzieci. Wydawnictwo Czelej, Lublin, 1997. 4. Jampel HD et al.: Fever and immunoregulation. III. Hypertermia augments the primary in vitro humoral immune response. J Exp Med 1983; 157: 1229-1238. 5. Roberts NJ Jr: Impact of temperature elevation on immunologic defenses. Rev Infect Dis 1991; 13: 462-472. 6. Austin TW, Truant G: Hyperthermia, antipyretics and function of polymorphonuclear leukocytes. Ann Med Assoc 1978; 118: 493-495. 7. Mackowiak PA, Paisance KI: Benefits and risk of antipyretic therapy. Ann NY Acad Sci 1998; 856: 214-223. 8. Kramer MS, Naimark L, Leduc DG: Parental fever phobia and its correlates. Pediatrics 1985; 75: 1110-1113. 9. Anon JB et al.: Sinus and allergy health partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130(Suppl. 1): 1-45. 10. Diagnosis and management of acute otitis media. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Pediatrics 2004; 113: 1451-1465. 11. Scottish Intercollegiate Guidelines Network, SIGN. Diagnosis and management of childhood otitis media in primary care. Guidlline No. 66. February 2003 http://www.sign.ac.uc./guidlines/fulltext/66/index.html. 12. Hryniewicz W i wsp.: Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego - 2009, w druku. 13. WHO Information PHA/CHW/86,1,3. 14. FDA. Approval for ibuprofen as antipyretic drug. Docket no. 98n-0056. List of approved drugs for which additional pediatric information may produce health benefits in the pediatric population, 1998. 15. Hopkins CS, Underhill S, Booker PD: Pharmacokinetics of paracetamol after cardiac surgery. Arch Dis Childhood 1990; 65: 971-976. 16. Gaudreault P et al.: Pharmacokinetics and clinical efficacy of intrarectal solution of acetaminophen. Can J Anaesthesiol 1988; 35: 149-152. 17. Birmingham FK et al.: Twenty four hour pharmacokinetics of rectal acetaminophen in children. Anaesthesiology 1997; 87: 244-252. 18. Van Lingen RA et al.: Pharmacokinetics of rectally administered single dose acetaminophen in preterm neonatess. Arch Dis Child Fetal Neonatal Ed 1999; 80: 59-63. 19. Scolnik D et al.: Comparison of oral versus normal and high-dose rectal acetaminophen in the treatment of febrile children. Pediatrics 2002; 110: 553-6. 20. Grenne JW, Craft L, Ghishan F: Acetaminophen poisoning in infancy. Am J Dis Child 1983; 137: 386-387. 21. Penna A, Buchanan N: Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol 1991; 32: 143-149. 22. Temple AR: Pediatric dosing of acetaminophen. Pediatric Pharmacology (New York) 1983; 3: 321-327. 23. TrÚluyer J et al.: Antipyretic efficacy of an initial 30-mg/kg loading dose of acetaminophen versus a 15-mg/kg maintenance dose. Pediatrics 2001; 108: 73. 24. Schachtel BP, Thoden WR: A placebo-controlled model for assaying systemic analgesics in children. Clin Pharmacol Ther 1993; 53: 593-601. 25. Schachtel BP, Furey SA, Thoden WR: Nonprescription ibuprofen and acetaminophen in the treatment of tension-type of headache.J Clin Pharmacol 1996; 36: 1120-1125. 26. Hńmńlńinen ML et al.: Ibuprofen or acetaminophen for the acute treatment in children: double blind, randomised, placebo-controlled, crossover study. Neurology 1997; 48: 103-107. 27. Bertin L et al.: Randomised, double blind, multicenter, controlled trial of ibuprofen v. acetaminophen (paracetamol) and placebo for treatment of symptoms of tonsillitis and pharyngitis in children. J Pediatr 1991; 119: 811-814. 28. Bertin L et al.: A randomised, double blind, multicentre trial on ibuprofen, acetaminophen and placebo for symptoms of acute otitis media. Fundam Clin Pharmacol 1996; 10: 387-392. 29. Davies N: Clinical pharmacokinetics of ibuprofen: The first 30 years. Clin Pharmacokinet 1998; 34: 101-154. 30. Langman MJ et al.: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078. 31. Henry D et al.: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566. 32. Moore N et al.: Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. Int J Clin Pract 2002; 56: 732-734. 33. Lesko SM, Mitchell AA: An assessment of the safety of pediatric ibuprofen. A practitioner-based randomised trial. JAMA 1995; 273: 929-933. 34. Lesko SM, Mitchell AA: The safety of acetaminophen and ibuprofen among children younger than two year old. Pediatrics 1999; 104: 951-952. 35. Meremikwu M, Oyo-Ita A: Paracetamol for treating fever in children. Cochrane Database of Syst Rev 2002, Issue 2. Art. No.: CD003676. DOI: 10.1002/14651858.CD003676. 36. Gupta H et al.: Role of paracetamol in treatment of childhood fever: a double-blind randomized placebo controlled trial. Indian Pediatr 2007; 44: 903-11. 37. Woollard M, Pitt K: Antipyretic prehospital therapy for febrile convulsions: Does the treatment fit? A literature review. Health Edu J 2003; 62: 23-8. 38. Perrott D et al.: Efficacy and safety of acetaminophen vs ibuprofen for treating children´s pain and fever. Arch Pediatr Adolesc Med 2004; 158; 521-6. 39. Goldman R: Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. Ann Pharmacother 2004; 38: 146-50. 40. Hay A et al.: Paracetamol plus ibuprofen for treatment of fever in children: randomized controlled trial. BMJ 2008; 337: 1302. 41. Walker RJ: Paracetamol, nonsteroidal anti-inflammatory drugs and nephrotoxicity. N Z Med J 1991; 182-3. 42. Vecchio M, Sundel E: Alternating antipyretics: Is this an alternative? Pediatrics 2001; 108: 1236-7. 43. Meremikwu M, Oyo-Ita A: Physical methods for treating fever in children. The Cochrane Database Syst Rev 2003; (2): CD004264. 44. Lenhardt R et al.: The effect of physical treatment in induced fever in humans. Am J Med 1999; 106: 550-555. 45. Chang AB et al.: Cough in children: definition and clinical evaluation. Med J Aust 2006; 184: 398-403. 46. Lee PCL, Jawad MS, Eccles R: Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory tract infection. J Pharm Pharmacol 2000; 52: 1137-1142. 47. Tukiainen H et al.: The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-2-sympathomimetic combination. Eur J Respir Dis 1986; 69: 95-99. 48. Taylor JAet al.: Efficacy of cough suppressants in children. J Pediatr 1993; 122: 799-802. 49. Paul IM et al.: Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics 2004; 114: 85-90. 50. Holmes PW, Barter CE, Pierce RJ: Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med 1992; 86: 425-29. 51. Allegra L, Bossi R: Clinical trials with the new antitussive levodropropizine in adult bronchitic patients. Arzneimittelforschung 1988; 38: 1163-6. 52. Chang CC, Cheng A, Chang A: Over-the-counter medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database of Syst Rev 2007, Issue 4, Art. No.: CD006088. 53. Ghafouri MA, Patil KD, Kass I: Sputum changes associated with the use of ipratropium bromide. Chest 1984; 86: 387-393. 54. Irwin R et al.: Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicans. Chest 1998; 114; suppl2: 133-181. 55. Elmer GT, Kapanci Y: Effects of ambroxol on pneumocyte type II cell. A morphological and biochemical study. Curr Probl Clin Biochem 1985; 13: 47-55. 56. Gibbs BF et al.: Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leucocytes and mast cells. Inflamm Res 1999; 48: 86-93. 57. Melillo, Cocco G: Ambroxol decreases bronchial hyperactivity. Eur J Respir Dis 1986; 69: 316-320. 58. Gene R et al.: Influence of ambroxol on amoxicillin levels in bronchoalveolar lavage fluid. Arzneimittelforschung 1987; 37: 967-968. 59. Fraschini F, Scaglione F, Scarpazza G: Effects of mucolitics on the bioavailability of antibiotics in patients with chronic respiratory diseases. Curr Ther Res 1988; 43: 734-742. 60. Zheng CH et al.: The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol 1999; 43: 107-113. 61. Zheng CH et al.: The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol 1999; 43: 107-113. 62. Gillissen A, Nowak D: Characterisation on N-acetylcysteine and ambroxol in antioxydant therapy. Respir Med 1998; 92: 609-623. 63. Marchioni CF, Moretti M, Muratori M: Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 1990; 168: 285-293. 64. Olivieri D et al.: Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration 1991; 58: 91-94. 65. Marchioni CF et al.: Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Therap 1995; 33: 612-618. 66. Braga P, Dal Sasso M, Zuccotti T: Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzeneimittelforschung 2000; 50: 739-746. 67. Braga P, Zuccotti T, Dal Sasso M: Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy 2001; 47: 208-214. 68. Balli F et al.: Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Therap 2007; 45: 16-22. 69. Poole P, Black PN: Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322; 1271. 70. Poole P, Black PN.: Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systc Rev 2006, Issue 3. Art. No.: CD001287.71. Taverner D, Latte J: Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001953. DOI: 10.1002/14651858.CD001953. pub3. 72. Griffin G et al.: Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003423. DOI: 10.1002/ 14651858.CD003423. pub2. 73. Gunn VL et al.: Toxicity of over-the-counter cough and cold medications. Pediatrics 2001; 108: 52. 74. Marinetti L et al.: Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. J Anal Toxicol 2005; 29: 738-43. 75. Boland DM et al.: Fatal cold medication intoxication in an infant. J Anal Toxicol 2003; 27: 523-6.76. Schroeder K, Fahey T: Should we advise Parents to administer over the counter cough medicines for acute cough? Systematic review of randomized controlled trials. Arch Dis Child 2002; 86: 170-5. 77. Schroeder K, Fahey T: Systematic review of randomized controlled trials of over the counter cough medicines for acute cough in adults. BMJ 2002; 324: 1-6. 78. De Sutter A, Lemiengre M, Campbell H: Antihistamines for the common cold. Cochrane Database of Syst Rev 2003, Issue 3. Art. No.: CD001267.

otrzymano/received: 2009-02-25
zaakceptowano/accepted: 2009-03-27

Adres/address:
*Piotr Albrecht
Klinika Gastroenterologii i Żywienia Dzieci WUM
ul. Działdowska 1, 01-184 Warszawa
tel.: (0-22) 452-32-66, fax: (0-22) 452-33-20
e-mail: palbrecht@kliniczny.pl

Pełna wersja artykułu Leczenie objawowe zakażeń dróg oddechowych dostępna w Czytelni Medycznej Borgis.

Copyright © Wydawnictwo Medyczne Borgis Sp. z o.o. 2007-2013
Chcesz być na bieżąco? Polub nas na Facebooku: strona Wydawnictwa na Facebooku